In a new partnership, BD, a medical technology company, has joined forces with Babson Diagnostics to broaden the availability of fingertip blood collection and testing technologies across the U.S. This collaboration integrates BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies, enabling blood test results from as little as six drops of capillary blood. This minimally invasive process eliminates the need for traditional venipuncture, making blood testing more accessible, particularly in underserved areas and locations lacking phlebotomy expertise. The streamlined procedure can be administered by trained healthcare workers, offering a practical solution to improve diagnostic access and reduce common barriers like fear of needles.
BD, with a 75-year history of innovation in blood collection, and Babson Diagnostics, renowned for its science-driven approach, aim to transform patient care with this technology. BetterWay blood testing, first launched in retail settings in 2024, is now expanding to ambulatory care sites, including urgent care clinics and pharmacies. By simplifying the blood collection process, the partnership supports healthcare organizations in increasing efficiency, enhancing patient satisfaction, and promoting health equity. Both companies share a commitment to advancing healthcare through innovative solutions that improve outcomes, reduce costs, and expand access for patients worldwide.
